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ABSTRACT
 
Lymphotoxin (LT) is a cytokine synthesized by
 
eytotpxiG T lymphocytes, B cells and natural killer
 
cells. This cytokine is very similar to tumor necrosis
 
factor (TNF) in both structure and in certain functions.
 
LT has been shown to induce cytotoxic, antiviral and
 
growth enhancing activities in a variety of cells
 
(Andrews et ai., 1990). LT has also been shown to be
 
essential for the proper development of peripheral
 
lymphoid organs in mice (Togni et al., 1994) and is
 
thought to play a role in the pathogenesis of certain
 
autoimmune diseases (Ruddle et al., 1990), but its role
 
in human development and in the immune response is still
 
poorly understood. One method that will help build upon
 
our knowledge of this cytokine involves placing site^
 
specific mutations in regions of the LT gene thought to
 
be important in receptor binding and in protein
 
structure. One such mutation involves an N-linked
 
glycosylation site present on the membrane bound form of
 
LT (mLT) but absent on the soluble form. By preparing a
 
mutant LT-^p gene that lacks this glycosylation site, it
 
will be possible to analyze a proposed model for LT
 
structure and ligand receptor interactions.
 
In this study, such a mutant was prepared using a
 
polymerase chain reaction (PGR) overlap extension
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technique to introduce a site-directed single base
 
substitution that destroyed the consensus sequence for
 
N-linked glycosylation, replacing an asparagine residue
 
with a serine residue. It is believed that this
 
substitution results in loss of the N-linked
 
glycosylation site while not significantly altering
 
protein conformation. The presence of the desired
 
mutation was confirmed using dideoxy DNA sequencing
 
analysis and the mutant cDNA cloned into the pcDNAl-amp
 
plasmid, E. Coll were transformed with this clone and
 
positive transformants used in the preparation of
 
maxiprep DNA. The DNA obtained was transfected into
 
GOS-7 mammalian cells and protein expression analyzed.
 
It was found that neither the mutant or wild-type LT-p
 
transfectants produced protein bands when labeled with
 
monoclonal LT-p antibodies and immunoprecipitated.
 
These results may indicate that LT-p is rapidly degraded
 
when expressed without LT-a.
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Introduction
 
The Gytokines are a diverse group of proteins that play
 
key roles in the effector phases of both the natural and
 
specific immune responses. Cytokines can be produced by and
 
act upon a wide variety of cell types to regulate immune and
 
inflammatory responses, as well as to influence the synthesis
 
and actions of other cytokines and their receptors. The
 
effects of many cytokines can vary depending on when and
 
where they are expressed and upon the presence of other
 
cytokines. It is this extreme variety of effects that helps
 
give the immune system its flexibility This pleotropic
 
response ability, although invaluable to the organism, has
 
made the study and understanding of these proteins rather
 
problematic. The mechanisms used by these molecules to
 
elicit such a wide and apparently very specific variety of
 
cellular reactions are still poorly understood. Over the
 
past decade, molecular and recombinant DNA technology has
 
given us some insight into how these molecules interact with
 
each other and with various receptors to cause the wide range
 
of responses seen in the immune response.
 
One family of cytokines that appears to play a major
 
role in the inflammatory response is the tumor necrosis
 
factor (TNF) family of cytokines. TNF, and the closely
 
related cytokine lymphotoxin (LT), regulate or participate in
 
all major phases of the cytotxic T lymphocyte (CTL) lytic
 
pathway (Ware at al., 1990). The importance of these
 
cytokines in the immune response is illustrated by the
 
mechanisms that viruses such as the Pox, Adeno and human
 
immunodeficiency virus (HIV), have developed to defeat or
 
utilize them (Smith at al., 1991; Horton at al., 1991;
 
Gooding, 1992). There is also evidence that these cytokines
 
play a role in certain autoimmune diseases (Ruddle et al.,
 
1990) and in genetic diseases linked to abnormal immune
 
function (Hollenbaugh at al 1992; Allen at al., 1993;
 
Korthauer at al., 1993; DiSanto at al., 1993; Smith at al.,
 
1993). I
 
TNF is expressed by a wide range of cell types in
 
response to antigens and other inflammatory stimuli (Old,
 
1985). Although the major source of TNF is the
 
lipopolysaccharide (LPS) activated mononuclear phagocyte, it
 
is also secreted by activated T cells, natural killer (NK)
 
cells and mast cells (Abbas, 1991). Both the soluble and
 
membrane-associated forms of TNF are composed of identical
 
subunits that associate to form a homotrimer. The first two
 
exons of TNF encode a region that contains a 76 amino acid
 
residue that functions as a membrane anchoring domain. This
 
26 kDa membrane bound form of TNF is the precursor of the
 
secreted form, which is released from the membrane anchoring
 
domain by proteolytic cleavage as a 17 kDa polypeptide.
 
(Kriegler et al., 1988).
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LT is a protein secreted by Cytotoxic T lymphocytes
 
(GTL)7 B cells and Natural Killer (NK) cells (Paul and
 
Ruddle/ 1988; Ware et al., 1992) as part of the inflammatory
 
and immune response. The predominant species of LT is a 25
 
kDa glycoprotein in humanS/ with a cDNA encoding for a 205
 
amino acid polypeptide. This protein is very closely related
 
to TNF and appears to play a role in the response of CTL
 
against virus infected and malignant cells (Ware et al.,
 
1990). Recently, LT has also been shown to play a role in
 
the proper development of peripheral lymphoid organs in mice
 
(Togni et al.f 1994), as well as being implicated in the
 
pathogenesis of certain autoimmune diseases (Ruddle et al.
 
1990).
 
The genes for TNF and LT have been cloned and are
 
closely linked in'the class III region of the major
 
histocompatability complex (MHC) on human chromosome 6. They
 
share 56% homology at the nucleotide level, 31% homology at
 
the amino acid level (Andrews et al., 1990) and also have
 
very similar intron-exon arrangements (Spies et al., 1986;
 
Nedwin et al., 1985). The secreted form of LT (LT-a) and TNF
 
share similar quaternary structures, assembling as homologous
 
trimers (Jones et al., 1989; Eck et al., 1988, Smith and
 
Baglioni, 1987).
 
Two receptors (TNFR) have been identified with high
 
affinity for TNF and LT^oc (Hohmann et al., 1989; Vilcek and
 
Lee, 1991). One, a 60 kDa protein (TNFRqq) is believed to be
 
sufficient for initiating cytotoxic function and responses
 
controlled by the nuclear binding protein NF-kB (Schultze et
 
al., 1992). The other is an 80 kDa receptor (TNFR90) important
 
in the mediation df T cell responses, the conferring of
 
protective tumor immunity In vivo and is the cause of many of
 
the toxic effects caused by TNF administration (Vandenabeele
 
et al., 1992; Van Ostade et al., 1993). Both receptors can
 
be shed following ip-rotein kinase C activation, causing down^
 
regulation of theicellular response and giving the organism
 
an additional method by which to modulate the immune reaction
 
to TNF or LT-a (Digel et al., 1992)• The binding of TNF to
 
the TNFR occurs at sites within the Cleft created at the
 
suhunit interface (Zhang etai., 1992), as demonstrated by
 
X-ray crystallography studies of LT-a bound to TNFRgp (Banner
 
et al., 1993). The signaling mechanisms used by the TNFR to
 
initiate cellular responses are not yet known, but it does
 
appear that multiple signaling pathways are present. The use
 
of these receptors by both LT-a and TNF explains certain
 
similarities in their biologic activity. In fact, the
 
original biological characterizations of TNF and LT showed LT
 
to be a much less potent cytokine In vitro and to function as
 
a partial agonist to TNF (Browning and Ribolini, 1989;
 
Andrews et al., 1990). This led to a hypothesis that LT was
 
simply a poorly redundant cytokine, although more recent
 
evidence would seem to indicate that this is not the case.
 
Like TNF, LT is also seen in a membrane bound form, but
 
it differs in the method of membrane attachment. Membrane
 
bound LT (mLT) isia heterotrimer containing LT-a subunit(s)
 
associated with the extracellular domain of a 33 kDa protein
 
(p33)(Browning et al., 1991) which also contains
 
transmembrane and cytoplasmic domains. Cloning of the gene
 
encoding p33 led to the discovery that it was homologous to
 
LT-a and TNF and was encoded next to the TNF and LT-a locus
 
on the MHO with similar intron-exon arrangements. These
 
similarities led to the designation of p33 as LT-p (Browning
 
et al., 1993)(Figure 1). The form of mLT most frequently
 
observed is a heterotrimer composed of two LT-a monomers
 
associating early in biosynthesis with a single LT-p monomer
 
(Androlewicz et al., 1992) (Figure 2). Trimers composed of
 
one LT-a and two LT-p subunits have also been observed, but no
 
naturally occurring LT-p homotrimers have yet been discovered.
 
Although little is known about the function of mLT, recent
 
evidence implicates mLT in the killing activity of lymphokine
 
activated killer (LAK) cells towards various tumor cell lines
 
(Horiuchi et al., 1994).
 
The known receptor binding sites on LT-a occur within
 
the cleft formed by the subunit interface (Banner et al.,
 
1993), which implies that up to three TNFR may bind a single
 
LT-a trimer complex (Pennica et al., 1992). This binding of
 
multiple receptors has distinct biological implications,
 
since receptor clustering may lead to a heightened or
 
different cellular response (Engelmann et al,, 1990). This
 
is even more signifleant in the ease of LT and TNF, where
 
different eombinations of TNFRgQ and TNFRqq reeeptors eould
 
potentially lead to a wide, variety of responses. This
 
heteromerie elustering has been found to play a role in the
 
pleotropie eellular respdnses to TNF (Van Arsdale et al., in
 
preparation) where different eellular responses to TNF oeeur
 
when heteromerie receptor elustering takes place versus those
 
seen when elustering of only one receptor type occurs. When
 
receptor clustering'does not occur, a weaker cellular
 
response is observed. This could explain the original
 
observations that LT binding to the TNFR led to a weaker
 
cellular response than that caused by TNF if the predominant
 
form of LT present was mLT, a form that could theoretically
 
bind at most one TNFR at the a-a subunit interface and hence
 
not lead to receptor clustering. A receptor specific for the
 
LT-p subunit interface has been discovered and has been
 
termed LT-pR (Crowe et al., 1994). Like the TNFR, this
 
receptor is a member of the TNF/Nerve Growth Factor (NGF)
 
family of receptors (Figure 3), a family characterized by
 
strong homology in the cysteine rich N-terminal portion of
 
the receptors (Goodwin et al., 1991). There is also evidence
 
to suggest that a receptor specific for the a-p interface does
 
exist (Crowe, personal communication), as evidenced by mLT
 
binding even in the presence of anti-LTpR and anti-TNFR
 
antibodies. This receptor has not yet been isolated and any
 
cellular signals generated by it are still unknown. These
 
discoveries implicate a wider role for LT in both the immune
 
response and in development than was previously thought and
 
demonstrate the importance of learning more about IT and the
 
mechanisms it utilizes by studying it at the molecular level.
 
Current models for the structure of mLT may lead to a
 
better understanding not only of its true function, but also
 
of the immune system in general. A model has been proposed
 
(Ware, unpublished data) in which the binding of the LT
 
ligand with its receptor is dependent upon the type of
 
subunit interface present (Figure 4). In this model, LT can
 
exist as one of four potential trimers. LT-a, the secreted
 
form of LT composed of three identical LT-asubunits (a3) has
 
already been structurally well characterized. Although
 
little is yet known about the 3-D structure of LT-p, its
 
sequence similarity with LT-a and TNF allow for some general
 
assumptions to be made in generating this model. The three
 
Other potential stiructures each contain LT-p subunits as Shown
 
in figure 4 (a2pi, aip2, p3). As the number of LT-p subunits
 
increases, the number Of TNFR binding sites decreases and the
 
number of LT-pR sites increases. Binding of the TNFR has been
 
shown to occur within the a-a subunit cleft and it is
 
theorized that LTr-pR binds within the P-P cleft. These
 
changes in receptor binding specificity would explain the
 
variety of cellular responses seen upon LT exposure and would
 
theoretically allow the organism to modulate its immune
 
response by altering the predominant species of LT or
 
receptor present.
 
One major difference between LT^a and LT-p subunits is
 
the presence of an N-linked glycosylation site on LT-p located
 
very near the region where TNFR binding occurs in LT^d(Figure
 
5). Based upon predictions of the 3-D conformation of the a-p
 
subunit interface, TNFR binding within this cleft may be
 
blocked by the carbohydrate attached to the N-linked
 
glycosylation site. If this is the case, this would be a
 
novel and previously unseen method by which nature has
 
regulated receptor binding by the presence or absence of a
 
carbohydrate.
 
In this study, LT-p was mutated to remove this N-linked
 
glycosylation site so that studies could be carried out to
 
examine the role of this site in LT function. The
 
preparation of a mutant LT-p gene lacking this site will allow
 
for further analysis of the role the sugar residue normally
 
present plays (if any) in stearically hindering the effective
 
binding of the TNFR bound by LT-a, which would potentially
 
lead to a different cellular response. It is also possible
 
that this sugar residue may play a role in trimer
 
construction by preventing three LT-p subunits from
 
interacting to form a trimer. This would explain the lack of
 
finding such a homotrimer in nature. By creating this mutant
 
gene, it will be possible to look at these and other
 
relationships between this residue and LT receptor binding
 
specificity and trimer formation, as well as cytotoxicty.
 
MATERIALS AND METHODS
 
Generatiozi o£ 5' and 3' PGR fragiRents Gontalning the
 
desli^ed mnt&tion. The amino acid consensus sequence for N-

linked glycosylation is aspafagine (N), any amino acid (X) ,■ 
serine (S)/threonine (T) (NXS/T) . The N residue of LT-p was 
substituted through the use of two pairs of PGR primers 
{Figure 6) . In one reaction, a 710 base pair (bp) fragment 
which included the LT-p sequence encoding amino acid residues 
1-225 was PGR amplified with the external 5' primer 
(5'pGDM8/LT-p) and an internal primer (3'LT-PN-S02) containing 
sequences encoding S instead of M in tlie middle region of the 
primer. In a second reaction a 3' external primer (3'LT­
p/Notl) and an internal primer (5'LT—PN-S02) were used to 
amplify LT^P amino acid residues 219 through the stop codon 
and 3' untranslated region (UTR) to yield a 107 bp fragment. 
This internal primer again contained sequences that replaced 
the N with an S and was complimentary to the other internal 
primer. Both sets of primers were obtained from Gruachem and 
diluted to a coneentratioh of 50 pM with distilled water 
(dHjO) . Reaction conditions for both fragments were 
identical, except the 5' reaction mixture contained 10% 
dimethylsulfoxide (DMSO) . Reactions were carried out in 0.6 
ml thin walled microfuge tubes (Midwest Scientific) in a 
thermal cycler (MJ Research Minicycler) . Each fragment was 
generated using 0.5 |xl (338 ng) of wild type LT-p cloned in
 
the pCDMB plasmid as a template. This template was a
 
generous gift from Dr. J. Browning (Biogen, Inc. Cambridge,
 
MA). The reaction also included 4 nl (200 jjM each)
 
deoxynucleotide triphosphate (dNTP) mix, 6 |xl (1.5 mM) MgCl2
 
and 10 |xl lOX PGR buffer (Perkin Elmer). The 5' fragment
 
also had 10 jil of iDMSO added to the tube. One microliter
 
(0.2 pM) of each of the appropriate 5' and 3' primers was
 
added and the reaction vessel brought up to a volume of 99.5
 
pi using dH20. The tubes were placed in the thermal cycler
 
and the temperature increased to 97°C for 1 minute, then 0.5
 
pi (2.5 Units) of DNA Ampli-Taq Polymerase (Perkin Elmer) was
 
added to each tube. The samples were then subjected to 30
 
cycles of denaturation (95°C/1 minute), annealing (58°C/1
 
minute) and extension (72°C/45 seconds). This was followed by
 
a 4 minute 72°C extension and the reactions were then cooled
 
to 4°C. The PGR products were run on a 3% Nu-Sieve agarose
 
(FMG) minigel in tris-acetate^EDTA (TAE) buffer (0.04M tris,
 
O.OOIM EDTA) for one hour at 100 volts and the desired bands
 
excised and purified using FMG Spin Bind columns. The DNA
 
products were eluted from the columns using 50 pi tris-EDTA
 
(TE) buffer (10 mM tris*Gl, 1 mM EDTA), pH 8.0, and stored at
 
-20°G.
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Joining of fragments by PGR Overlap Extension to
 
obtain full length mutant. The 5' and 3' fragments were
 
combined following gel purification to yield the full length
 
mutant DNA via an overlap extension technique (Figure 7).
 
Ten microliters DMSO, 10 |j.l lOX PGR buffer, 6 jil (1,5 mM)
 
MgClj, 4 |i.l (200 pM each) dNTP's, and 200 ng of each of the 5'
 
and 3' fragments obtained above were mixed and the volume
 
brought up to 97.5 p.1 with dH20. This mixture was denatured
 
at 95°C for 1 minute, and 0.5 ml (2.5 units) Tag polymerase
 
added. Five cycles were then carried out using a 95°C/1
 
minute denaturation, 45°C/2 minute annealing and 72°C/3 minute
 
extension step. Following this, 1 pi (0.2 pM) of the
 
5'pCDM8/LT-pII primer and 1 pi (0.2pM) of the 3'LT-p/Not 1
 
primer were added and 25 additional cycles completed with a
 
modification in the annealing step to 50°C/2 minutes. A
 
72°C/10 minute final extension step was performed and the
 
samples cooled to 4°C. Sixty microliters of this reaction was
 
run through the FMC Spin Bind PGR Product Purification column
 
and the product run on a 3% Nu-Sieve agarose gel.
 
Sequence confirmation of mutation. DNA sequence
 
confirmation of the desired mutation was performed using a
 
Sequenase PGR Product Sequencing Kit (United States
 
Biochemical). Three microliters (60 ng) of the mutated DNA
 
was used as a template in each sequencing reaction.
 
Sequences were run from both the 5V and 3' ends using the 3'
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 outside primer and a 5' primer (5' Seq)(Figure 6) that codes
 
for an 18 base sequence located 100 bp upstream from the
 
mutation. First, an annealing mix was prepared using the
 
template and 1 |il (0.2 jiM) of the appropriate primer. The
 
volume of this mix was brought up to 10 p-l with dHjO. The
 
mixture was denatured by heating in the thermal cycler at
 
100°C for 3 minutes and then rapidly cooled in an ice-water
 
bath for 5 minutes and kept cool on ice. While cooling, 2.5
 
|j.l of each termina.tion mix (A,C,G and T) were placed in
 
individual microfuge tubes. These tubes were prewarmed to
 
37°C in a water bath. A labeling mix was prepared by making a
 
1:5 dilution of the labeling mix supplied with the kit in
 
dH20. To the ice-cold annealing mix the following was added:
 
2 |il reaction buffer, 1 (j,l 0.IM dithiothreitol (DTT), 2 |a.l 1:5
 
diluted labeling mix, 0.5 nl [^ssjdATP (Amersham, 1000 Gi/mmol
 
specific activity) and 2jil (3.2 units) Sequenase DNA
 
Polymerase. This mixture was allowed to incubate at room
 
temperature for 5 minutes and then 3.5 |j.l was added to each
 
of the four termination tubes and incubated for 5 minutes at
 
37°C. The reactions were then stopped using 4 |j.l of stop
 
solution and the samples briefly heated to 75°C immediately
 
prior to loading onto the gel. The samples were run on a 6%
 
polyacrylimide gel in an IBI Base Runner 100 electrophoresis
 
apparatus. Samples were run at 50 watts constant power for 6
 
hours (three sets of each sample loaded at two hour
 
intervals) maintaining gel temperature at approximately 50°C.
 
12
 
Following the run, the gel was rinsed in a 5% Acetic Acid/5%
 
Methanol bath for 15 minutes and then transferred to Whatman
 
3MM filter paper and dried on a Labconco gel drier for 1 hour
 
at 75°C, exposed to Fuji X-Ray film for 72 hours then
 
developed and the sequence analyzed.
 
Cloning of mutant DNA in pcDNAl-amp plasmid. Once the
 
mutant sequence was confirmed, the DNA was ligated into a
 
pcDNAl-amp plasmid (Invitrogen) for future amplification and
 
analysis. The pcDNAl-amp plasmid (Figure 7) is an
 
approximately 4.8 kb high copy number shuttle vector
 
expressed in both prokaryotic and eukaryotic systems that
 
confers ampicillin resistance in E. Coli. First, 500 ng of
 
the desired DNA was digested with the restriction enzymes
 
Not-1 (recognition sequence GCGGCCGC) and Hind III
 
(recognition sequence A'^AGCTT)(7 Units each, GIBCO) at 37°C
 
for 6 hours and purified using the Spin Bind PGR Purification
 
System to remove the end fragments and unwanted enzymes. One
 
microgram of pcDNAl^amp was also digested in this manner and
 
gel purified to remove the polylinker and to prepare cohesive
 
ends for ligation. Seyeral ligation reactions were then set
 
up as follows. As a control, a 0:1 insert to vector (vector
 
only) ligation was performed using lOO ng cut pcDNAl-amp, 2
 
10.1 lOX ligase buffer and 0.5 |ol (2.5 Units) T4 DNA ligase
 
(GIBCO). The reaction volume was brought up to 20 ul using
 
dHjO. 2:1 and 3:1 insert to vector ligations were also
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prepared as above. The reactions were allowed to continue
 
for 16 hours at 16°C and then were placed on ice. Twenty
 
microliters of GIBCO JM 109 frozen supercompetent cells were
 
placed in prechilled Falcon 2059 tubes and 1 (il of a 1:5
 
dilution of each ligation mix in dHjO was placed into the
 
appropriate tubes; This mixture was kept on ice for 30
 
minutes, heat shocked at 42°C for 45 seconds and placed back
 
on ice for 2 minutes, then 980 jxl of SOC medium prewarmed to
 
37°C was added to each tube. The tubes were incubated at 37°C
 
with shaking at 225 RPM for 1 hour, then 200 |xl of each mix
 
was plated on Luria Broth (LB) plates supplemented with
 
ampicillin at a concentration of 100 ji.g/ml (amp 100) and
 
incubated overnight at 37°C. Single colonies were selected
 
and grown in 2 ml LB/amp 100 at 37°C overnight. Minipreps
 
were performed on 1.5 ml of each culture using the Promega
 
Magic Miniprep kit. First the cultures were pelleted in a
 
microfuge at 14,000 rpm for 2 minutes and the cells
 
resuspended in 100 |j,l of Promega resuspension buffer, then 1
 
ml of Promega binding resin was added and the solution mixed
 
gently. This solution was then placed in a 3 ml syringe and
 
gently pushed through a Promega Magic Miniprep column,
 
followed by a wash with 2 ml of 80% isopropanol wash buffer
 
and elution with 50 jil TE prewarmed to 65°C. The remaining
 
0.5 ml of culture was saved as stock for future cultures by
 
adding 150 |il of 80% glycerol and storing at -20°C. The DNA
 
obtained was digested with Not-^l and Hind III and run on a 1%
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agarose gel to confirm the presence of the desired 760 bp
 
fragment.
 
Maxiprep of pcDNAl-ainp/LT--p Mutant DNA. A culture was
 
prepared using 100 |a.l of the stored 0.5 ml Coli culture
 
which had tested positive for the mutant insert previously in
 
the miniprep and 200 ml of LB/amp 100. This culture was
 
grown overnight at 37°C. To obtain the desired plasmid DNA
 
the culture was Centrifuged at 12,O0Oxg for 15 minutes at 4°C
 
and the supernatant discarded. The pellet was dissolved in
 
10 ml of resuspension buffer containing 100 jig/ml RNase A,
 
0.1 mM Tris/Hei and 10 mM EDTA, pH 8.0. Once dissolved, 10
 
ml of lysis buffer containing 200 mM NaOH and 1% SDS was
 
added and then the tube was inverted 5 times and incubated at
 
room temperature for 5 minutes. After incubation, 10 ml of
 
lysis neutralization buffer containing 3.0 M potassium
 
acetate (KAc), pHT5.5 was then added, the tube inverted
 
several times and then put on ice for 20 minutes. The tube
 
was mixed again and centrifuged at 30,000xg for 30 minutes at
 
4°C. While the mixture was centrifuging, 10 ml of column
 
equilibration buffer containing 750 mM NaCl, 50 mM MOPS
 
(3-[N-Morpholino]propanesulfonic acid), 15% ethanol and 0.15%
 
Triton X-100 at a pH of 7.0 was added to a QIAGEN tip-500
 
column and allowed to enter by gravity flow. This was
 
followed by the supernatant obtained from the centrifuged
 
cell lysate. Once the lysate had flowed through the column.
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 2 washes were performed using 30 ml each of wash buffer
 
containing 1.0 M NaCl, 50 mM MOPS and 15% ethanol at a pH of
 
7.0. The column bound DNA was then eluted using 15 ml of
 
elution buffer containing 1.25 M NaCl, 50 mM Tris/HCl and 15%
 
ethanol at a pH of 8.5. To the eluate, 0.7 volumes of room
 
temperature isopropanol was added and the mixture centrifuged
 
for 30 minutes at 15,OO0xg at 4°C. The pellet was then washed
 
with 15 ml ice-cold 70% ethanol and centrifuged again. The
 
DNA pellet was allowed to dry for 10 minutes and was then
 
redissolved in 0,5 ml TE pH 8.0. The dNA obtained was 
■ 'v' ' ■ ^ ^ 
analyzed on a 1% agarose gel. 
COS-7 cell culture. GOS-7 mammalian (monkey kidney) cells
 
were maintained ip.Dulbecco's Modified Eagles Medium (DMEM)
 
supplemented with 10% fetal calf serum,, 2 mM glutamine,
 
penicillin and streptomycin (100 ug/ml each) in 10% CO2/90%
 
ambient atmosphere at 37°C. The cells were passaged every 3-4
 
days upon reaching approximately 80-90% confluence.
 
GOS-7 cell trahsfection. 2.5 x 10^ cells were plated into
 
60 mm Culture dishes the day prior to transfection and grown
 
in DMEM as above.: The cells were rinsed twice with 5 ml warm
 
phosphate buffered saline (PBS) and then with 5 ml of serum
 
free DMEM. A DNA/Liposome solution was prepared containing 1
 
|j,g DNA, 2 ml serum free DMEM and 10 |il LipofectACE (GIBCO) in
 
a 5 ml polystyrene tube. Tubes were prepared containing
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LT-a, LT-p, LT-p mutant and control vector (Cav.Not) DNA. The
 
solution from each tube was added to a plate and the plates
 
incubated at 37°C in 10% CO2/90% ambient atmosphere for 5
 
hours. 2 ml of DMEM supplemented with 20% fetal calf serum
 
was then added and the plates incubated at 37°C overnight.
 
The media was then replaced with 3 ml of DMEM containing 10%
 
fetal calf serum and incubated an additional 48 hours.
 
Biosyn'bhe'biG labeling of COS-7 calls. The monolayer of
 
transfected cells was washed twice with warm PBS. To each
 
dish, 1 ml of cys/met-free DMEM containing 10% dialyzed fetal
 
calf serum and glutamine was added and the dish incubated 5
 
minutes at room temperature. A 150 |a.Ci/ml ^^S^cys/met label
 
(ICN Trans label ~10 |j,Ci/ml) was then added and the plates
 
incubated at 37°C for 3 hours with occasional rocking. The
 
supernatant was then removed and transferred to a microfuge
 
tube. The monolayers were lysed with 1 ml/dish ice-cold
 
lysis buffer (20 mM Tris-HCl, pH 8.0, 150 mM NaCl, 2% Nonidet
 
P-40 (NP-40), 1 mM EDTA, 40 mM iodoacetamide and 2mM
 
phenylmethylsulfonyl flouride) for 10 minutes at 4°C. The
 
lysates were then transferred to a microfuge tube and the
 
tubes centrifuges at 13,000 rpm for 10 minutes at 4°C. Each
 
sample was then ttansferred to a fresh microfuge tube for
 
immunoprecipitation. Each tube was precleared by adding 1 \ig
 
of mouse IgG and 40 (xl protein G-Sepharose (GammaBind G-

Sepharose, Pharmacia). The tubes were capped tightly and
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rocked 1 hour at 4°G, then centrifuged briefly to pellet the
 
protein Q beads and the supernatant was then removed and
 
placed in a new tube. A mixture of 1 m-S each of three
 
monoclonal anti-LT-p antibodies (B27, B9 and C37)(BIOGEN) was
 
added along with 40 |il/tube of protein G-Sepharose to the
 
tubes containing the Cav.Not control, LT-p and the LT—p
 
mutant. One microgram of an anti-LT-a monoclonal antibody
 
(NC2)(Biogen) along with the protein G beads was added to the
 
LT-a transfection control tube. The tubes were capped
 
tightly and rocked 1 hour at 4°C, then centrifuged briefly to
 
pellet the protein G beads. The samples were aspirated and
 
the beads washed three times with wash buffer containing 20
 
mM Tris (Ph 8,0), 0.5% NP-40, 150 mM NaCl, 0.5% deoxycholate
 
and 0.05% sodium dodecyl sulfate (SDS) and once with PBS­
azide (N3) then resuspended in 50 jil 2x SDS-PAGE sample buffer
 
containing 100 mM Tris-Cl (pH 6.8), 200 mM dithiothreitol, 4%
 
SDS, 0.2% bromophenol blue, 20% glycerol plus 4% 2-mercapto­
ethanol and heated for 5 minutes at 100°C.
 
SDS^Polyacrylimide gel electrophoresis (SDS-PAGE).
 
The samples were then loaded on a 12% SDS-polyacrylamide gel
 
and run overnight at 10 mA constant current to separate
 
proteins. The gel was then soaked for 30 minutes in 1 M
 
sodium salicylate (fluor) and transferred to Whatman 3MM
 
filter paper and dried at 75°C for 1 hour. The dried gel was
 
18
 
exposed to X-Omat AR film (Eastman Kodak) and a Cronex
 
intensifying screen, (Du Pont) for 24 hours at -70°C and
 
developed.
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RESULTS
 
Prepara'tion of 5' and 3' PGR fragments containing the
 
mutation. Through the use of the two sets of primers
 
discussed previously, the expected fragments were obtained.
 
Agarose gel eletrophoresis of the PGR products showed bands
 
at approximately 710 bp and 107 bp respectively (Figure 9).
 
The optimization of reagent concentrations and cycling
 
parameters resulted in the amplification of only the desired
 
fragments while avoiding the generation of non-specific and
 
unwanted fragments.
 
joining of fragi^en'ts by PGR Overlap Extension yields
 
full-length mutant. Application of the overlap extension
 
technique using the two fragments generated above yielded a
 
760 bp fragment (Figure 9) which represents the full length
 
mutated LT-p cDNA. The PGR reaction yielded approximately 1
 
|ig of DNA. Optimization of reagent and cycling parameters
 
eliminated hon-specific fragments.
 
Sequence confirmation of mutation. The use of the
 
Sequenase PGR Product Sequencing kit allowed for rapid
 
sequence analysis of the PGR product. Both the 5' and 3' DNA
 
strands contained the desired mutation (figure 10) and no
 
Other random mutations were observed within 100 bp either
 
side of the site-directed mutation on either strand.
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Cloning of mutant DNA in pcDNAl-amp plasmid.
 
Restriction digests of the vector and the PCR product
 
resulted in the creation of compatible cohesive ends that
 
allowed for specific ligation of the insert in the proper
 
orientation into the vector while avoiding religation of
 
vector alone. No transformants were noted in the vector only
 
control plate, while the 2:1 and 3:1 plates both contained 20
 
transformed colonies. Miniprep DNA from these colonies were
 
analyzed by restriction digests and all analyzed colonies
 
contained the expected 760 bp insert (figure 11).
 
Maxiprep of pcDNAl-amp/LT-p mutant DNA. A culture that
 
tested positive for the insert in the miniprep was used to
 
grow a large culture for the maxiprep. Approximately 250|j.g
 
of pcDNAl-amp/LT-p mutant DNA was obtained from a 200 ml
 
culture.
 
COS-7 cell transfection, biosynthetic labeling and
 
SDS-'PAGE. Immunoprecipitation of cell lysates using
 
monoclonal antibodies specific for LT-a or LT-p confirmed that
 
COS-7 cells were successfully transfected. The
 
autoradiograph of the labeled precipitates showed a band at
 
26 kDa representing the LT-a sample and indicates a
 
successful transfection. However, no bands were evident in
 
samples transfected with either LT-p or mutant LT-p.
 
Precipitation of these samples was attempted using three
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different monoclonal antibodies to ensure the epitope had not
 
been lost during the mutagenesis, however none of the
 
monoclonal antibodies precipitated confirming proteins in
 
either LT-p sample.
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Figure 1. Schematic diagram of the region of
 
chromosome 6 containing the LT/TNF locus. TNF, LT-a
 
and LT-p are linked within 10 kb in the MHC on human
 
chromosome 6. The exon^intron arrangements for each gene are
 
similar. LT-p is coded for in an opposite direction from TNF
 
and hT-tx. Restriction map shows sites for EcoRI (E), Xhol
 
(X), Hindlll (H), Bglll (B), Kpnl (k), PstI (P) and Ncol (N).
 
(From Browning et al., 1993)
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Figure 2. A working model for LT biosynthesis and
 
secretion. Newly formed LT-a and LT-p monomers can
 
associate within the lumen of the endoplasmic reticulum to
 
form trimers composed of a3, a2pi or alp3 subunits. These
 
subunits are then processed within the Golgi and transported
 
to the cell surface for expression as mLT (a2pi or aip2) or
 
secreted LT (a3). (Adapted from Androlewicz et ai., 1992)
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Figure 3. Members of the TNF ligand and receptor
 
family. For the ligands, an open box indicates the region
 
of homology in the extracellular domain where the receptor
 
binding sites are located, while the filled boxes indicate
 
the cytoplasmic, transmembrane and extracellular stalk
 
regions. The number of residues in each region are
 
indicated. The receptor cys-rich repeat homology regions are
 
shown as open boxes. Stripped boxes in the cytoplasmic
 
region indicate homology. N or O indicate likely sites of
 
glycosylation and P represents sites of phosphorylation
 
(Ware, unpublished data).
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Figure 4. Proposed model of LT-aP complexes. The four
 
potential trimers that are proposed for LT and the possible
 
receptor binding interfaces for each. The a3 trimer could
 
bind up to three TNFR which are specific for the a-a cleft.
 
The aZpi trimer could potentially bind only one TNFR and one
 
LT-pR, which are specific for the P-P cleft. The aip2 could
 
not bind a TNFR but could bind up to two LT-pR. The P3, which
 
has not been observed to occur in nature, could bind three
 
LT—PR. The cleft formed at a-p subunit interfaces is thought
 
to bind an as yet unidentified receptor (Ware, unpublished
 
data).
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%■ 
LT-P LT-a. 
Figure 5. Molecular model of LT-a/LT-p interface. The 
LT-p subunit contains transmembrane and cytoplasmic domains 
not present on the LT-a subunit. LT-p also contains an N-
linked glycosylation site very near the proposed binding 
region for the TNFR in the interface cleft. It is possible 
that this N-linked glycosylation site positions a 
carbohydrate that stearically blocks TNFR binding to mLT. 
The dark blue and yellow areas indicate regions of homology 
and the green area is a conserved proline thought to function 
in subunit association (Ware, unpublished data) . 
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Ouliside Primers: 
5'pCDM8/LT-p 
5'CGACTCACTATAGGGAGACC3' Melting Temp. 54°C 
3'LT-p/Not-1 
5'CGCGGCCGCACTCGGACCACGC3' MeIting Temp. 80°C 
Inside Primers: 
5'LT-pN-SOl 
5'GTGACTGATGCTGACGTAGAC3' Melting Temp. 64°C 
3'LT-pN-SOl 
5'GTGTACGTCAGCATCAGTCAC3' Melting Temp. 64°C 
5'Sequencing Primer: 
5'LT-p/Seq 
5'GAGACGGTGACTCCAGTG3' Melting Temp. 58°C 
Figure 6. Primers utilized in PGR and sequencing
 
reactions. Primers used in the PGR reactions include the
 
outside primers, 5'pGDM8/LT-p and 3'LT-p/Not-1. These primers
 
allow for amplification of the entire LT-p gene and the 3'LT­
p/Not-1 also inserts a JSIot-l site in the 3' untranslated
 
region. Inside primers include 5'LT-pN-SOl and 3'LT-pN-S02.
 
These primers were used to insert the desired single base
 
substitution (underlined) into the two fragments generated
 
for use in the overlap extension procedure, changing the
 
sequence to code for serine instead of asparagine. 5'LT-p/Seq
 
was used to generate the 5' strand used in sequencing, this
 
primer annealed approximately 100 bp upstream from the
 
mutation site. A 3' strand was also generated for sequencing
 
using the 3'LT-p/Not^l primer.
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Figure 7. Exsunple of sife-dlrected mufagenesis using
 
overlap extension PGR. Specific base changes can be made
 
using the overlap extension technique. Two separate PGR
 
fragments are prepared, utilizing 5' and 3' non-mutated
 
outside primers and complimentary internal primers that
 
contain the desired base changes. These two fragments are
 
amplified in separate PGR procedures, then the purified
 
products combined, denatured and annealed and extended to
 
form a full length template containing the mutation. The 5'
 
and 3' outside primers are then added and another full PGR
 
cycle run to amplify a full length mutant sequence.
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Figure 8. Map of the pcDNAl-amp plasmid used as a
 
shuttle vector. The pcDNAl/Amp plasmid contains a strong
 
promoter for eukaryotic expression, a ColEl sequence for high
 
copy replication in E. Coll and ampicillin resistance in E,
 
Coli for positive selection (Map supplied by Invitrogen).
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Figure 9. Agarose gel showing fragments made during
 
PGR site directed mutagenesis procedure. Lane 1
 
contains molecular weight markers (BioMarker Low). Bands are
 
at 1000, 700^ 525, 500, 400, 300, 200, 100 and 50 bp. Lane 2
 
shows the 5' fragment at approximately 710 bp. Lane 3
 
contains the 3' fragment of approximately 107 bp. Lane 4
 
shows the overlap extension product obtained by combining the
 
fragments from lanes 2 and 3. This fragment represents the
 
full length mutated LT-p gene of 760 bp and contains
 
restriction enzyme sites for Hind III at the 5' end and Not-1
 
at the 3' end.
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A C G T
 
3' sequence
 
Mutated Sequence: 5' GGTGAfiCATC 3'
 
3' GGAGTfiGTAG 5'
 
10. Sequence confirmation of desired mutation.
 
The presence of the desired sequence was confirmed using
 
dideoxy-DNA sequencing as seen on the 3' sequence shown in
 
this autoradiograph. The site^specific mutation was the
 
single base substitution underlined and in bold. This
 
substitution results in an amino acid change from asparagine
 
to serine, leading to a loss of the N-linked glycosylation
 
site in the protein product.
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Figure 11. Restriction digest of clone from pcDNA-amp.
 
Following transfection, DNAminipreps were performed to
 
confirm insertion of the cloned DNA. Restriction digests of
 
the miniprep DNA with Not-1 and Hind III yielded a 760 bp
 
fragment, indicating the mutated gene has been successfully
 
inserted into the pcDNAl-amp plasmid. The left lane contains
 
known molecular weight markers of Lambda DNA cut with the
 
restriction enzyme Bst EII,
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Figure 12. Autoradiograph of protein
 
immunoprecipitation. Transfection of COS-7 cells with
 
LT-a, LT-p and LT-p mutant followed by immunoprecipitation
 
with monoclonal antibodies yielded a band at 26 kD for LT-a
 
indicating a successful transfection. Known weight markers
 
are at 200, 97, 69, 46, 30 and 14 kDa. No bands are present
 
for either LT-p sample. The lack of bands may indicate LT-p
 
is being rapidly degraded when no LT-a is present.
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Figure 13. Flow cytometry data showing surface 
expression of LT—a/p on COS-7 cells. The relative 
flourescence created by staining LTa/p cotransefected COS-7 
cells with anti'-LT-a is shown as a solid line and the 
background flourescence due to control IgG staining is shown 
as a dashed line. Note no relative change when LT-a is 
expressed alone, this is because the LT-a is not retained on 
the cell surface. LT-p when expressed alone is not stained 
with the anti-LT-a, but when expressed with LT-ain a 
cotransfection experiment it causes LT-a to be targeted to 
the cell surface and retained, where it is stained by the 
antibody. (From Browning et ai., 1993) 
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DISCUSSION
 
The preparation of a site-specific DNA mutant of LT-p
 
was shown to be possible using the PGR overlap extension
 
technique. Although this technique was first demonstrated to
 
be a practical and efficient method of site-specific
 
mutagenesis several years ago, when utilized with the LT-p
 
gene several modifications were required. The LT—p gene is
 
very C-G rich in its 5' end, resulting in excessively high
 
melting temperatures and rapid reannealing of the two DNA
 
strands. This made the generation of a 5' mutant DNA
 
fragment very difficult and impractical using standard PGR
 
protocols. After trying a wide variety of reaction
 
conditions without success, the reactions were attempted in a
 
vessel containing 10% DMSO. Although not normally used in
 
PGR protocols utilizing Taq polymerase, DMSO was used
 
previously in Klenow-mediated PGR reactions (Scharf at al.,
 
1986). Although DMSO is known to reduce the effectiveness of
 
Taq polymerase by approximately 50%, its use in these
 
reactions allowed for the generation of mutant 5' fragments
 
at relatively good levels, yielding approximately 1 ng of
 
mutant DNA per 100 |j.l reaction. It is uncertain which
 
parameters are affected by inclusion of 10% DMSO, but DMSO
 
may affect the melting temperature of the primers, the
 
thermal activity profile of the Taq polymerase and/or the
 
degree of product strand separation during denaturation.
 
Even at denaturation temperatures of 99°G, reactions involving
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the 5' end of this gene attempted without DMSO were not
 
successful/ while addition of 10% DMSO allowed reactions to
 
take place with denaturation temperatures of 95°C. Inclusion
 
of 10% DMSO was also required in the subsequent overlap
 
extension protocols to create full length mutant LT-p cDNA.
 
Once the full length cDNA was produced, it was sequenced
 
in the region surrounding the mutation site to confirm the
 
presence of the mutation and the absence of other random
 
mutations. Full length sequencing will be necessary
 
eventually since random mutations can be created while using
 
Taq polymerase at a rate approaching 1/4000 base pairs (Ho et
 
al., 1989). Since sequencing is time consuming and tedious,
 
full length sequericing will be performed only if changes in
 
binding characteristics, cytotoxicity or trimer formation
 
using the mutant DNA are observed in future assays. The use
 
of the Sequenase PGR sequencing kit with the 5'Seq and
 
3'LT-p7Not-l primers allowed for direct sequencing of both
 
strands of the PGR product a distance of 100 bp either side
 
of the desired mutation. No mutations other than the desired
 
mutation were observed and the sample was then digested with
 
Not 1 and Hind III arid cloned into the pcDNAl-amp plasmid.
 
E. Coli cells were subsequently transformed to generate high
 
yields of the desired mutant DNA (approximately 250 |j.g per
 
maxi-prep).
 
Following isolation of the amplified plasmid from E.
 
Coll, the mutant DNA was transfected into GOS-7 cells to
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obtain protein expression in a mammalian expression system
 
for immunoprecipitation analysis. A sampling of three
 
different monoclonal antibodies were used to ensure the
 
desired epitope had not been inadvertently removed by the
 
mutation. Results of the immunoprecipitation were
 
inconclusive. LT-p was not expressed at high enough levels to
 
observe any protein in the autoradiograph (Figure 12). If
 
the protein had precipitated as expected, a band would have
 
been seen at approximately 33 kDa in the wild type LT-p sample
 
and a band of slightly greater mobility would have been
 
expected for the LT-p lacking the N-linked glycosylation site
 
due to lack of the sugar residue. A control transfection of
 
LT-a precipitated with an anti-LT-a monoclonal antibody
 
yielded the expected band at 26 kDa. Several other attempts
 
to precipitate wild type LT-p from COS-7 cells have also
 
failed to detect protein. Flow cytometry analysis of cells
 
transfected with LT-p has shown that very small quantities of
 
the protein are present when expressed in conjunction with
 
LT-a (Figure 13). The promoter on the pcDNAl-amp plasmid is
 
a strong promoter, so fairly high levels of protein
 
expression should be expected. This would seem to indicate
 
that rapid protein degradation may be taking place.
 
Co-transfection of GOS-7 cells using both LT-a and LT-p has
 
been attempted with no LT-p evident on the autoradiograph (not
 
shown). It is not known whether a sufficient number of cells
 
are receiving both plasmids to yield distinguishable bands of
 
38
 
a-Pco-expression on the autoradiograph. An interesting
 
feature of these qotransfections is that the relative level
 
of LT-a expression drops as the amount of LT-p transfected .
 
increases. This would seem to indicate that the presence of
 
LT-pis having some effect on LT-a expression, but the nature
 
of this effect is unclear.
 
In baculovirus—infected insect cells, LT-p is expressed
 
alone or with LT-a in cotransfected cells at very high levels
 
(Crowe, unpublished data). This data may indicate that LT-p
 
alone (which has never been observed naturally) contains a
 
signal sequence that directs the LT-p proteins down a
 
degradative pathway when expressed in mammalian cells. In
 
insect cells, this pathway may be overwhelmed, so the protein
 
is expressed. However, in these cells, the protein is seen
 
in forms not normally observed, from monomers to aggregates,
 
indicating that even though it is expressed, it is expressed
 
in states not normally seen. When LT-a is coexpressed with
 
LT-p, heterotrimers are seen similar to those found in normal
 
mammalian cells. Together, this may indicate a change in the
 
3-dimensidnal conformation is occurring upon subunit
 
interaction which signals a secretory pathway. Another
 
possibility is that the LT-a subunit contains a secretory
 
signal and this subunit blocks the degradative signal on LT-p
 
when the SubunitS are together. To examine if some signal in
 
the transmembrane or cytoplasmic domains are signaling for
 
protein degradation, a soluble chinieric LT-p/myc construct was
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prepared (Biogen) in which the transmembrane and cytoplasmic
 
regions of LT-p had been removed and replaced with the myc
 
protein start sequence. This chimeric protein was expressed
 
by COS-7 cells at levels similar to those seen for LT-a
 
(Growe et al., 1994). This would indicate that the signal
 
for the degradative pathway is located somewhere in the
 
transmembrane or cytoplasmic domains of LT-|3.
 
Further analysis pf liT through the use of the mutant DNA
 
created in this research will have to await the insertion of
 
the mutant gene into a baculovirus vector. Although the data
 
generated by transfection of COS-7 cells was interesting and
 
valuable/ it has not answered any questions concerning the
 
role of the N-linked glycosylation site in receptor binding
 
interactions or in trimer association. Further studies are
 
in progress to attempt expression of the mutant LT-p in the
 
baculovirus expression system. Cotransfections using LT-a
 
and LT-p in the baculovirus system should yield adequate
 
protein to address these questions.
 
The importance of working out the protocols required to
 
prepare LT-p mutants using the overlap extension technique
 
cannot be underestimated and will allow many important
 
questions about LT-p and the immune response to be answered in
 
the future. This; project has led to the preparation of one
 
LT-p mutant and has also worked out easy and rapid protocols
 
that should allow'for future research using LT-p mutants to be
 
done quickly and efficiently.
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